R. Jiménez‐Puya

Infections in Moderate to Severe Psoriasis Patients Treated with Biological Drugs Compared to Classic Systemic Drugs: Findings from the BIOBADADERM Registry

P. Dávila‐Seijo, E. Daudén, M.Á. Descalzo et al. · Journal of Investigative Dermatology · 2016 · 123 citations · Full text

Classic Systemic Drugs, Psoriatic Arthritis, Clinical Dermatology +6

Obesity and Psoriasis: Inflammatory Nature of Obesity, Relationship Between Psoriasis and Obesity, and Therapeutic Implications

J.M. Carrascosa, V. Rocamora, R. Fernández‐Torres et al. · Actas Dermo-Sifiliográficas · 2014 · 102 citations · Full text

Metabolic Disorder, Immunology, Pathology +20

Survival of classic and biological systemic drugs in psoriasis: results of the <scp>BIOBADADERM</scp> registry and critical analysis

P. Dávila‐Seijo, E. Daudén, G. Carretero et al. · Journal of the European Academy of Dermatology and Venereology · 2016 · 97 citations

Body mass index in patients with moderate‐to‐severe psoriasis in Spain and its impact as an independent risk factor for therapy withdrawal: results of the Biobadaderm Registry

J.M. Carrascosa, M. Vilavella, I. García‐Doval et al. · Journal of the European Academy of Dermatology and Venereology · 2013 · 75 citations

Risk of adverse events in psoriasis patients receiving classic systemic drugs and biologics in a 5‐year observational study of clinical practice: 2008–2013 results of the Biobadaderm registry

G. Carretero, E. Daudén, Francisco Vanaclocha Sebastián et al. · Journal of the European Academy of Dermatology and Venereology · 2014 · 65 citations · Full text